International urogynecology journal · 2025
Failure Rate, Time to Failure, and Associated Risk Factors: Polyacrylamide Hydrogel Injection for the Treatment of Stress Urinary Incontinence in a Large Cohort.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kelly Erin, Yearwood Camille, Rajwani Alykhan, Sanaee May, Groves Paul, Batara Jesse
Аннотация
INTRODUCTION: Stress urinary incontinence (SUI) imposes a high healthcare burden and significantly affects quality of life and daily functioning. While midurethral slings remain the standard surgical treatment, periurethral bulking with polyacrylamide hydrogel (PAHG) is increasingly utilized. Existing studies focus on PAHG success, and have been limited by small sample sizes and short follow-up. This study aimed to assess PAHG failure risk, time to failure, and the likelihood of repeat injections, while identifying associated risk factors.
HYPOTHESIS: Periurethral injection with PAHG for SUI in a complex patient cohort, will have a significant failure rate within 24 months, with a mean time to failure under 2 years and a high rate of repeat SUI surgery.
METHODS: We conducted a retrospective review of all SUI patients who underwent PAHG injection at a single center from January 1, 2014, to August 31, 2020. We defined subjective PAHG failure as patient-reported recurrent SUI symptoms.
RESULTS: Among the 256 patients who underwent PAHG injection during the study period, 35.9% (N = 92) experienced PAHG failure within 2 years (mean time to failure 9.061 months (SD 11.60 months)). Repeat PAHG injection was performed in 12% (N = 30), while 15% (N = 38) underwent other incontinence surgery. Multivariable analysis did not show any factors associated with increased risk of PAHG failure.
CONCLUSIONS: Polyacrylamide hydrogel for SUI, in medically and surgically complex patients, has similar failure rates and mean time to failure, as in uncomplicated patients.
HYPOTHESIS: Periurethral injection with PAHG for SUI in a complex patient cohort, will have a significant failure rate within 24 months, with a mean time to failure under 2 years and a high rate of repeat SUI surgery.
METHODS: We conducted a retrospective review of all SUI patients who underwent PAHG injection at a single center from January 1, 2014, to August 31, 2020. We defined subjective PAHG failure as patient-reported recurrent SUI symptoms.
RESULTS: Among the 256 patients who underwent PAHG injection during the study period, 35.9% (N = 92) experienced PAHG failure within 2 years (mean time to failure 9.061 months (SD 11.60 months)). Repeat PAHG injection was performed in 12% (N = 30), while 15% (N = 38) underwent other incontinence surgery. Multivariable analysis did not show any factors associated with increased risk of PAHG failure.
CONCLUSIONS: Polyacrylamide hydrogel for SUI, in medically and surgically complex patients, has similar failure rates and mean time to failure, as in uncomplicated patients.